Skip to main content
Equibles

Stephen Mayo, Ph.D.

Board Member

Allogene Therapeutics, Inc. (ALLO)

Equibles does not estimate personal net worth.

Get an email with a short summary when Allogene Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get ALLO alerts

About Stephen Mayo, Ph.D.

Stephen Mayo, Ph.D. is recorded as Board Member at Allogene Therapeutics, Inc. (ALLO) since July 8, 2022. Allogene Therapeutics, Inc. reported in an 8-K filed July 12, 2022 that Stephen Mayo, Ph.D. was appointed Class III director, effective July 8, 2022. Allogene Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Allogene Therapeutics, Inc. includes Zachary Roberts, M.D., Ph.D. (CEO and Board Member), Geoffrey Parker (CFO), Tim Moore (CTO) and 4 others.

“On July 8, 2022, the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased the authorized number of directors on the Board from eleven to twelve, and appointed Stephen Mayo, Ph.D. as a Class III director of the Company to fill the newly created vacancy, effective immediately, with a term of office expiring at the Company’s 2024 annual meeting of stockholders.”
Allogene Therapeutics, Inc. Form 8-K, filed July 12, 2022 · Read the filing

Affiliation history

Company network

Leadership on record at Allogene Therapeutics, Inc.

Recent activity